Cargando…
TRANSLATIONAL RESEARCH-03 MULTIPLE MECHANISMS MODULATE TEMOZOLOMIDE RESISTANCE AND ARE POTENTIAL TARGETS FOR GLIOBLASTOMA THERAPY.
Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Temozolomide (TMZ) is the only drug currently been used for treatment of newly diagnosed GBM patients but the benefit from this agent has been hampered by the primary and secondary resistance. Thus, there is a strong need for...
Autores principales: | Kitange, Gaspar, Sarkaria, Jann |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616571/ http://dx.doi.org/10.1093/noajnl/vdad121.056 |
Ejemplares similares
-
TRANSLATIONAL RESEARCH-02 THE KEYSTONE CYTOKINE, INTERLEUKIN-6, A KEY TARGET AND “ORGANIZING PRINCIPLE” FOR GLIOBLASTOMA THERAPY: A DECADE OF TRANSLATIONAL PROGRESS FROM GENOMICS TO THE LABORATORY AND TO A MULTICENTER CLINICAL TRIAL
por: Brem, Steven
Publicado: (2023) -
Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma
por: Daniel, Paul, et al.
Publicado: (2022) -
GLIOMA-02 HISTOPATHOLOGIC AND MOLECULAR PROFILE OF GLIOMAS: A 9-YEAR RETROSPECTIVE STUDY OF CASES DIAGNOSED IN LAGOS NIGERIA
por: Odukoya, Lateef, et al.
Publicado: (2023) -
TIPS-03 A PHASE 1 STUDY OF GALLIUM MALTOLATE (GAM) IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)
por: Connelly, Jennifer, et al.
Publicado: (2023) -
MENINGIOMA-03 FUNCTIONAL OUTCOME AFTER SURGERY FOR INTRACRANIAL MENINGIOMA AT THE KENYATTA NATIONAL HOSPITAL
por: Kagasi, Travor, et al.
Publicado: (2023)